Island Pharmaceuticals Limited (ASX:ILA)

Market Cap	100.89M
Revenue (ttm)	118.91K -90.6%
Net Income	-3.92M
EPS	-0.02
Shares Out	269.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	369,255
Average Volume	376,710
Open	0.3900
Previous Close	0.3750
Day's Range	0.3750 - 0.4200
52-Week Range	0.1200 - 0.6300
Beta	0.21
RSI	44.78
Earnings Date	Feb 22, 2026

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ILA

Financial Performance

In 2025, Island Pharmaceuticals's revenue was 118,910, a decrease of -90.57% compared to the previous year's 1.26 million. Losses were -3.92 million, 36.9% more than in 2024.